FILE:LIFE/LIFE-8K-20120113171053.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
 
 
Item 8.01 - Other Events
On January 13, 2012, Life Technologies Corporation (the "Company") sent notice to holders of the Company's 1.5% Convertible Senior Notes, Due 2024 (the "Notes") that the Company elects to redeem all of its outstanding Notes on February 15, 2012 pursuant to Section 3.1 of the Indentures, dated February 19, 2004 and December 14, 2004 (each an "Indenture", and collectively, the "Indentures") between Life Technologies Corporation (formerly known as Invitrogen Corporation) and U.S. Bank National Association. Holders of the Notes have until 5:00 p.m. Eastern Time on February 14, 2012 to convert their Notes into shares of the Company's Common Stock and / or cash in accordance with the applicable Indenture.
U.S. Bank National Association is the trustee (the "Trustee") for the holders of the Notes under the Indentures. All questions relating to the mechanics of the redemption or conversion of the Notes should be directed to Paula Oswald at U.S. Bank National Association, telephone number (213) 615-6043.
This announcement is only a summary of certain provisions of the Notes and the Indentures. A complete explanation of the conversion rights of holders of the Notes, as well as the procedures required to convert the Notes, is set forth in the applicable Indenture. All holders are urged to review the conversion provisions contained in the Notes and the applicable Indenture in their entirety.
On January 13, 2012, the Company issued a press release regarding the redemption of the Notes. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: January 13, 2012

Exhibit 99.1
Life Technologies Announces Redemption of 1.5% Convertible Senior Notes Due 2024
CARLSBAD, Calif., January 13, 2012 (PR Newswire)  Life Technologies Corporation (NASDAQ: LIFE) announced today that it has given notice of its intention to redeem all of the outstanding 1.5% Convertible Senior Notes due 2024 (the "2024 Convertible Notes") on February 15, 2012. As of December 31, 2011 there was $450,000,000 in aggregate principal amount of the 2024 Convertible Notes outstanding. The redemption notice provided includes CUSIP Numbers: 46185RAG5, 46185RAH3 and 46185RAK6.
The 2024 Convertible Notes are convertible at any time prior to 5:00 p.m. Eastern Time, February 14, 2012 at a rate of 19.603 shares of common stock per $1,000 principal amount of the 2024 Convertible Notes surrendered. The 2024 Convertible Notes surrendered for conversion will be settled in cash and stock in accordance with the provisions of the indentures.
The U.S. Bank National Association, the trustee for the 2024 Convertible Notes, is mailing a Notice of Redemption to all registered holders of the 2024 Convertible Notes on January 13, 2012. Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2024 Convertible Notes may be obtained from the U.S. Bank National Association by calling (800) 934-6802.
About Life Technologies
(www.lifetechnologies.com)
is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://
Life Technologies Corporation
www.lifetechnologies.com.
Contact Information:
Investor Relations
760-603-7208
ir@lifetech.com


